# Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

> **NCT02446132** · PHASE3 · TERMINATED · sponsor: **Otsuka Pharmaceutical Development & Commercialization, Inc.** · enrollment: 1197 (actual)

## Conditions studied

- Agitation in Patients With Dementia of the Alzheimer's Type

## Interventions

- **DRUG:** AVP-786

## Key facts

- **NCT ID:** NCT02446132
- **Lead sponsor:** Otsuka Pharmaceutical Development & Commercialization, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-11-13
- **Primary completion:** 2024-09-06
- **Final completion:** 2024-09-06
- **Target enrollment:** 1197 (ACTUAL)
- **Why stopped:** The AVP-786 program was discontinued, the recruitment was stopped and all participants are no longer being examined or receiving intervention.
- **Last updated:** 2025-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02446132

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02446132, "Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02446132. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*